Showing 5361-5370 of 7863 results for "".
- LEO Pharma Launches Study of Delgocitinib for PPPhttps://practicaldermatology.com/news/leo-pharma-launches-study-of-delgocitinib-for-ppp/2474972/LEO Pharma announced today the initiation of a phase 2a trial looking at the safety and efficacy of delgocitinib cream in adults with palmoplantar pustulosis (PPP). According to a news release from the manufacturer, the DELTA
- Study: Most Global Melanoma Cases Attributable to UV Exposurehttps://practicaldermatology.com/news/study-most-global-melanoma-cases-attributable-to-uv-exposure/2474874/A new global analysis of cutaneous melanoma (CM) shows ultraviolet radiation (UVR) as the primary driver behind the majority of CM cases worldwide in 2022. Researchers used updated incidence estimates from GLOBOCAN 2022 (exclud
- FDA Panel Urges Removal of Talc from Consumer Products Due to Cancer Linkhttps://practicaldermatology.com/news/fda-panel-urges-removal-of-talc-from-consumer-products-due-to-cancer-link/2474873/A U.S. Food and Drug Administration (FDA) advisory panel has reinforced longstanding concerns over the carcinogenic potential of talc, urging the agency to restrict its use in foods, drugs, and cosmetics. Citing more than thre
- ADA: Dermatologists Need to Lead on Climate Healthhttps://practicaldermatology.com/news/ada-dermatologists-need-to-lead-on-climate-health/2474867/The American Dermatological Association (ADA) has issued its first comprehensive policy statement on climate change, publishing the document in the Journal of Investigative Dermatology.
- HADLIMA Cleared for Substitution with Humira in All Forms: FDAhttps://practicaldermatology.com/news/hadlima-cleared-for-substitution-with-humira-in-all-forms-fda/2474836/The US Food and Drug Administration (FDA) has granted full interchangeability status to adalimumab-bwwd (HADLIMA™), a biosimilar of Humira® (adalimumab), across all forms and concentrations, according to a press release from Organon.
- EFFISAYIL 2: Spesolimab Associated with Long-Term GPP Reliefhttps://practicaldermatology.com/news/effisayil-2-spesolimab-associated-with-long-term-gpp-relief/2474835/Patients with generalized pustular psoriasis (GPP) experienced sustained symptom control and quality of life (QoL) improvements when treated with spesolimab, according to an analysis of results from the EFFISAYIL 2 trial. Re
- Analysis Forecasts 140% Rise in Basal Cell Carcinoma by 2050https://practicaldermatology.com/news/analysis-forecasts-140-rise-in-basal-cell-carcinoma-by-2050/2474797/The global burden of skin cancer among adults aged 65 and older has increased steadily over the past three decades and is expected to continue rising through 2050, according to a new analysis of Global Burden of Disease (GBD) Study data.
- Analysis: Air Pollution Linked with Elevated Disease Activity in Bullous Pemphigoidhttps://practicaldermatology.com/news/analysis-air-pollution-linked-with-elevated-disease-activity-in-bullous-pemphigoid/2474733/New retrospective research indicates a relationship between ambient air pollution and increased disease activity in patients with bullous pemphigoid (BP), compared to those with pemphigus. Researchers analyzed 617 clinic visit
- Blended Wavelength Laser Hair Removal Demonstrates Safety and Efficacy Across Skin Toneshttps://practicaldermatology.com/news/blended-wavelength-laser-hair-removal-demonstrates-safety-and-efficacy-across-skin-tones/2474667/New data demonstrates how dual-wavelength laser devices may offer a safer, more inclusive approach to hair removal for all skin tones. At the recent American Society for Laser Medicine and Surgery (ASLMS) annual meeting, Nkemjika Ugonabo, MD, MPH, FAAD, Assistant Professor at Albert Einste
- GW Prior Certification Coordinator Offers Tips at ElderDermhttps://practicaldermatology.com/news/GW-Prior-Certification-Coordinator-Offers-Tips-ElderDerm/2474666/There are no shortcuts to getting dermatologic treatments authorized by Medicaid and insurance companies, George Washington University Department of Dermatology’s prior certification coordinator said at the ElderDerm 2025 Conference in Washington, DC. Effort and diligence are the keys when